ClinicalTrials.gg
RecruitingNCT06347029Updated Apr 4, 2024

Evaluation of Endothelial Dysfunction Using the "Flow Mediated Dilation" Test in a Population of Chronic Renal Failure Patients at Different Stages, and Evaluation of the Role of Antiphospholipid Antibodies

An interventional study of Urine sampling and Blood sampling in Chronic Renal Failure, sponsored by Brugmann University Hospital. Recruiting at 1 site in Belgium. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-04.

Sponsored by Brugmann University Hospital · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Registered 5 months after the study started (first participant enrolled Oct 2023, registered Mar 2024).
  • Started Oct 2023; still recruiting 3 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 62 studies in Kidney Failure, Chronic with a site in Belgium — 8 open to participants now, 14 under way, 3 of them phase 3. Kidney Failure, Chronic · Belgium.

Planned enrollment
12th of 45
200 · median 71
Started
2023
with 3 others
No phase
23 of 62
3 open now
Primary completion
2024-12
later than 2 of 13 live
Registered
56th of 62
by date

Among the 62 studies in Kidney Failure, Chronic with a site in Belgium, this one is the 12th largest by planned enrollment of the 45 interventional ones that give a count, is one of 4 that started in 2023, is one of 23 with no phase, reaches primary completion later than 2 of the 13 other live ones, and was the 56th registered.

Kidney Failure, Chronic

2,115 studies on the registry are indexed under Kidney Failure, Chronic; 277 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

8 of the 62 studies in Kidney Failure, Chronic with a site in Belgium are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 170 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 62 studies in Kidney Failure, Chronic with a site in Belgium, or all of them as a file.
02

Study summary

The vascular endothelium is an organ in its own right, playing, among other things, a primordial role in the control of vascular tone. This vascular tone is ensured by pro-dilator mediators (nitric oxide (NO), prostacyclins (PGI2)), or vasoconstrictors (endothelin, thromboxane A2 or PGH2).Uremic toxin accumulation in chronic kidney disease (CKD) is a well-known factor in endothelial dysfunction, often associated with higher cardiovascular risk. This association is also present for terminal chronic kidney disease characterized by the need to resort to an extra-renal purification technique (in-center hemodialysis (HD), daily home hemodialysis (HDQ), peritoneal dialysis) or to resort to renal transplantation.

For HD to be effective, it is essential that the blood flow rate passing through the dialyzer is greater than 300ml/min. This imperative requires that any hemodialysis patient have specific vascular access (dialysis catheter or arteriovenous fistula (AVF)) to ensure these flow rates. The vascular access of choice is the arteriovenous fistula , because it is associated with a lower risk of infection and lower morbidity and mortality. Making an arteriovenous fistula consists of surgically creating an anastomosis between a vein and an artery.

Complications of arteriovenous fistula are common. Arteriovenous fistula maturation may be delayed (maturation delay) or even absent. Drainage veins and/or anastomoses can also be the site of stenosis or thrombosis. The pathophysiology of these complications is complex and multifactorial. Among the risk factors for these complications (delay or absence of maturation, stenosis thrombosis), the positivity of antiphospholipid antibodies (aPL) can be cited, as well as endothelial dysfunction.

Antiphospholipid syndrome (APS) is an autoimmune disease causing a thrombotic phenotype. This is an acquired thrombophilia. In the general population, the prevalence of antiphospholipid antibodies is around 0.5%; this prevalence is far from rare in hemodialysis, since it represents up to 37% in dialysis patients. In a retrospective study carried out at Brugmann University Hospital in 2023 , on 115 patients with AVF and in whom aPL dosages were available, the prevalence of persistent positivity (2 positive dosages spaced more than 12 weeks apart) was 21%.

Interestingly, a third of the cohort presented an antibody profile that did not allow them to be classified according to the classification criteria in force. This group corresponds to patients with a single positive dosage, either not recontrolled or recontrolled negative. This group was called Fluctuating. This fluctuating group was associated with arteriovenous fistula complications in a 2019 study.

Endothelial dysfunction is also implicated in the pathophysiology of APS. In clinical practice, the "flow mediated dilation" (FMD) test makes it possible to assess endothelial dysfunction in vivo. It involves the phenomenon of post-occlusive hyperemia which is mainly linked to NO and endothelium-dependent vasodilation. In the brachial artery, NO is the sole mediator of FMD. Endothelial dysfunction according to FMD has been described in populations with advanced chronic kidney disease, as well as patients with cardiovascular diseases. Hemodialysis patients with delayed/absence of arteriovenous fistula maturation have more pathological FMDs compared to dialysis patients without fistula problems. However, the additive role of aPL in this different population has not been studied in terms of endothelial dysfunction by FMD.

The objective of this study is to evaluate the weight of antiphospholipid biology on endothelial dysfunction in hemodialysis patients, using the FMD test.

  1. Compare endothelial dysfunction by FMD according to the stage of chronic kidney disease and in comparison to a control group without chronic kidney disease.
  2. Characterize the FMD pre or post dialysis and according to the duration of the long (for example between Thursday and Sunday) vs. short (between Tuesday and Thursday) inter-dialytic period.
  3. Evaluate the relationship between endothelial dysfunction according to FMD, aPL positivity and arteriovenous fistula complications in hemodialysis patients.
  4. Evaluate the risk factors associated with endothelial dysfunction according to FMD, and in particular evaluate the impact of antiphospholipid antibodies.
  5. Evaluate the correlation between endothelial dysfunction according to FMD and other markers of endothelial dysfunction (urinary NO and metabolites of urinary NO, PGI2, endothelin, PGH2).
03

Conditions studied

  • Chronic Renal Failure
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with Chronic kidney disease from stage G3a to G5
  • Healthy volunteers

Exclusion criteria

Exclusion Criteria:

  • Patients with chronic kidney disease stage G5 with no dosage available of antiphospholipid antibodies.
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Chronic kidney disease at stage G3a

    Renal clearance according to CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) between 60 and 45 ml/min/1.73m²

    Procedure: Urine sampling · Procedure: Blood sampling · Device: Flow mediated dilatation test

  • Experimental
    Chronic kidney disease at stage G3b

    Renal clearance according to CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) between 45 and 30 ml/min/1.73m²

    Procedure: Urine sampling · Procedure: Blood sampling · Device: Flow mediated dilatation test

  • Experimental
    Chronic kidney disease at stage G4

    Renal clearance according to CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) between 30 and 15 ml/min/1.73m²

    Procedure: Urine sampling · Procedure: Blood sampling · Device: Flow mediated dilatation test

  • Experimental
    Chronic kidney disease at stage G5 not dialyzed

    Renal clearance according to CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) less than 15 ml/min/1.73m² but not dialyzed

    Procedure: Urine sampling · Procedure: Blood sampling · Device: Flow mediated dilatation test

  • Experimental
    Chronic kidney disease at stage G5 with dialyze

    Patients who undergo dialyze

    Procedure: Urine sampling · Procedure: Blood sampling · Device: Flow mediated dilatation test

  • Active comparator
    Control

    Healthy volunteer patient, without existing kidney disease

    Procedure: Urine sampling · Procedure: Blood sampling · Device: Flow mediated dilatation test

Interventions

  • ProcedureUrine sampling

    Urine sampling

  • ProcedureBlood sampling

    Blood sampling

  • DeviceFlow mediated dilatation test

    The flow mediated dilation (FMD) test is the most commonly utilized, non-invasive, ultrasound assessment of endothelial function in humans.

06

What researchers measure

Primary outcomes

  1. Nitric oxide (NO) plasma level

    Nitric oxide (NO) plasma level

    Time frame: pre-intervention

  2. Endothelin 1 (ET-1) plasma level

    Endothelin 1 (ET-1) plasma level

    Time frame: pre-intervention

  3. E-Selectine plasma level

    E-Selectine plasma level

    Time frame: pre-intervention

  4. P-Selectine plasma level

    P-Selectine plasma level

    Time frame: pre-intervention

  5. Intercellular Adhesion Molecule 1 (ICAM-1) plasma level

    Intercellular Adhesion Molecule 1 (ICAM-1) plasma level

    Time frame: pre-intervention

  6. Interleukin 6 (IL-6) plasma level

    Interleukin 6 (IL-6) plasma level

    Time frame: pre-intervention

  7. Nitric oxide (NO) urine concentration

    Nitric oxide (NO) urine concentration

    Time frame: pre-intervention

  8. Endothelin 1 (ET-1) urine concentration

    Endothelin 1 (ET-1) urine concentration

    Time frame: pre-intervention

  9. Tumour Necrosis Factor alpha (TNF alpha) urine concentration

    Tumour Necrosis Factor alpha (TNF alpha) urine concentration

    Time frame: pre-intervention

  10. Interleukin 6 (IL-6) urine concentration

    Interleukin 6 (IL-6) urine concentration

    Time frame: pre-intervention

  11. Flow mediated dilatation test result (%)

    Flow-mediated dilation (FMD) is a non-invasive vascular function test that measures the change in artery diameter in response to reactive hyperemia. The result of the test is expressed as a percentage.

    Time frame: pre-intervention

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Dec 2024, 14 months after the start.

Of 349 non-industry interventional studies with no phase under Kidney Failure, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 47. This study's planned 14 months is below that.

Counting every sponsor, half of 427 studies reached it within 22 months; a quarter within 8 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2024
First posted
Apr 4, 2024
StartActual
Oct 17, 2023
Primary completionEst.
Dec 31, 2024
CompletionEst.
Dec 31, 2024
Last update
Apr 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06347029
Responsible party
Tatiana Besse-Hammer (Head of clinical trial unit, Brugmann University Hospital) — Principal investigator
First posted
Apr 4, 2024
Start date
Oct 17, 2023
Primary completion
Dec 31, 2024 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
Apr 4, 2024

Study contacts

Maxime Taghavi
Contact
Maxime.TAGHAVI@chu-brugmann.be
003224772644

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion